Massive Bio CEO Selin Kurnaz will attend the 14th SCOPE Summit, which focuses on advances and innovations in all aspects of clinical trials, and will be held in Orlando, Florida, on February 6-9.
SCOPE Summit, one of the most important annual gatherings in the field of clinical research, will take place on February 6-9, 2023, at Rosen Shingle Creek, a hotel and resort in Orlando, Florida. Celebrating its 14th anniversary, the summit will feature conferences, plenary keynote sessions, and interactive discussions focused on advances and innovative solutions in all aspects of clinical trial planning, management and operations. Other highlights of SCOPE Summit will include the 7th annual Participant Engagement Awards and SCOPE’s 2nd Annual Masters of Clinical Research Golf Tournament.
The summit, which attracted more than 2,300 attendees last year, brings together leaders in clinical operations and research to discuss and share ideas about critical issues facing the industry, which this year will include addressing racial inequalities in clinical trials, conducting clinical trials in the face of global crises (the COVID-19 pandemic, war, hyperinflation, supply chain disruptions), using next-generation data sources, and many others.
One leading voice in the world of clinical trials who will be attending SCOPE Summit is Selin Kurnaz, PhD, who is CEO and co-founder of Massive Bio, which is the only company in the biotechnology industry with an oncology-focused artificial intelligence program. “SCOPE brings together those driving innovation in digital health. As Massive Bio, we are excited to meet our current and new customers and business partners” says Kurnaz.